Ryan Arthur F's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Apr 3, 2026
- Accession no.
- 0001104659-26-039613
- Filed
- Apr 3, 2026
- Trade date
- Apr 1, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 9 non-derivative transactions. Open-market sales total $77.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ryan Arthur FCIK 0001187443 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | Common Stock | SSaleDisposed | −1 | $771.32 | −$771.32 | 17,702 | Direct | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −3 | $772.76 | −$2,318.28 | 17,699 | Direct | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −8 | $773.59 | −$6,188.72 | 17,691 | Direct | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −8 | $774.58 | −$6,196.64 | 17,683 | Direct | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −14 | $775.58 | −$10,858.12 | 17,669 | Direct | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −13 | $776.62 | −$10,096.06 | 17,656 | Direct | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −9 | $777.42 | −$6,996.78 | 17,647 | Direct | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −4 | $778.24 | −$3,112.96 | 17,643 | Direct | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −40 | $779.71 | −$31,188.4 | 17,603 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.